OverviewSuggest Edit

STAAR Surgical is a developer, manufacturer, and marketer of implantable lenses and companion delivery systems used in ophthalmic surgery. The company provides EVO Visian implantable Collamer lenses (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia, as well as Hyperopic ICL to treat far-sightedness. It also offers minimally invasive intraocular lenses (IOLs) for use in cataract surgical procedures, sells surgical products and other related instruments, devices, and injector parts, and manufactures AquaFlow devices for the treatment of glaucoma.

TypePublic
Founded1982
HQMonrovia, US
Websitestaar.com
Employee Ratings3.4

Latest Updates

Employees (est.) (Dec 2018)475(+35%)
Job Openings16
Revenue (FY, 2018)$124 M(+37%)
Share Price (Jan 2020)$42.3

Key People/Management at STAAR Surgical

Caren Mason

Caren Mason

President and Chief Executive Officer
Deborah Andrews

Deborah Andrews

Chief Financial Officer
Scott Barnes

Scott Barnes

Chief Medical Officer
Keith Holliday

Keith Holliday

Chief Technology Officer
Samuel J. Gesten

Samuel J. Gesten

Chief Legal Officer and Corporate Secretary
William Goodmen

William Goodmen

Vice President, Global Human Resources
Show more

STAAR Surgical Office Locations

STAAR Surgical has offices in Monrovia, Shanghai, Hamburg, Urayasu and in 3 other locations
Monrovia, US (HQ)
1911 Walker Ave
Shanghai, CN
Room 1505, Building II, No.533 Loushanguan Road, ARCH Busniess Center, Changning District
Hamburg, DE
Harksheider Str. 3
Urayasu, JP
1-chōme-5-2 Irifune
Singapore, SG
229 Mountbatten Rd, 02 Mountbatten Square
Barcelona, ES
Avinguda Meridiana, 216, 1o
Show all (7)

STAAR Surgical Financials and Metrics

STAAR Surgical Revenue

Embed Graph
View revenue for all periods
STAAR Surgical's revenue was reported to be $123.95 m in FY, 2018 which is a 36.8% increase from the previous period.
USD

Revenue (Q3, 2019)

39.1m

Gross profit (Q3, 2019)

29.1m

Gross profit margin (Q3, 2019), %

74.4%

Net income (Q3, 2019)

2.4m

EBIT (Q3, 2019)

3.3m

Market capitalization (22-Jan-2020)

1.9b

Closing stock price (22-Jan-2020)

42.3

Cash (27-Sept-2019)

112.3m

EV

1.8b
STAAR Surgical's current market capitalization is $1.9 b.
Annual
USDFY, 2016FY, 2017FY, 2018

Revenue

82.4m90.6m124.0m

Revenue growth, %

7%10%37%

Cost of goods sold

24.1m26.3m32.4m

Gross profit

58.4m64.3m91.5m
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Revenue

19.3m21.0m20.1m20.4m21.9m23.5m27.1m33.9m31.8m32.6m39.7m39.1m

Cost of goods sold

6.3m6.3m5.2m5.8m6.5m6.6m7.7m8.7m7.9m8.4m9.8m10.0m

Gross profit

13.0m14.6m14.9m14.6m15.5m16.8m19.4m25.2m23.9m24.2m29.9m29.1m

Gross profit Margin, %

67%70%74%72%71%72%72%74%75%74%75%74%
Annual
USDFY, 2016FY, 2017FY, 2018

Cash

14.0m18.5m103.9m

Accounts Receivable

16.3k17.9m25.9m

Prepaid Expenses

1.9m2.4m3.0m

Inventories

14.8m13.3m16.7m
Annual
USDFY, 2016FY, 2017FY, 2018

Net Income

(12.1m)(2.1m)5.0m

Depreciation and Amortization

2.9m3.4m2.5m

Inventories

1.8m312.0k(4.2m)

Accounts Payable

1.0m(2.5m)243.0k
Quarterly
USDY, 2019

EV/EBIT

534 x

EV/CFO

111.3 x

Debt/Equity

0.1 x

Debt/Assets

0.1 x

Financial Leverage

1.3 x
Show all financial metrics

STAAR Surgical Operating Metrics

FY, 2016FY, 2018

Countries Covered

60 75

Patents Issued

67 62

Patents Pending

20 24

Trademarks

11 10
Show all operating metrics

STAAR Surgical Acquisitions / Subsidiaries

Company NameDateDeal Size
Canon StaarDecember 29, 2007
Frigitronics, Inc.January 01, 1987
STAAR Japan Inc.
STAAR Optical Equipment
STAAR Surgical AG
STAAR Surgical PTE. LTD
Technology (Shanghai) Co., LTD

STAAR Surgical Revenue Breakdown

Embed Graph

STAAR Surgical revenue breakdown by business segment: 5.4% from Other Surgical Products, 81.5% from Implantable Collamer Lenses and 13.1% from Intraocular Lenses

STAAR Surgical revenue breakdown by geographic segment: 19.8% from Japan, 39.5% from China and 40.7% from Other

STAAR Surgical Online and Social Media Presence

Embed Graph

STAAR Surgical News and Updates

STAAR Surgical Celebrates One Million Lens Milestone for Implantable Collamer Lens (ICL)

LAKE FOREST, Calif.--( )--Apr. 10, 2019-- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer, and marketer of implantable lenses and companion delivery systems for the eye, today announced that more than one million Visian implantable Collamer lenses (ICLs) have been implanted …

STAAR Surgical Blogs

STAAR Surgical Celebrates Visual Freedom with Jorgensen Family

STAAR Surgical Celebrates Visual Freedom with Jorgensen Family Content Import Wed, 10/09/2019 - 07:01 STAAR Surgical Celebrates Visual Freedom with Jorgensen Family Oct 09,2019 This release is a backfill from a News Wire General  Opht…

STAAR Surgical to Report Third Quarter Results on October 30, 2019

STAAR Surgical to Report Third Quarter Results on October 30, 2019 Content Import Wed, 10/09/2019 - 07:00 STAAR Surgical to Report Third Quarter Results on October 30, 2019 Oct 09,2019 This release is a backfill from a News Wire General …

STAAR Surgical Announces FDA IDE Clinical Study Approval

STAAR Surgical Announces FDA IDE Clinical Study Approval Content Import Tue, 08/27/2019 - 07:00 STAAR Surgical Announces FDA IDE Clinical Study Approval Aug 27,2019 This release is a backfill from a News Wire General EVO/EVO+ VISIAN® …

STAAR Surgical Announces Submission of Presbyopia Clinical Trial Data; Proprietary EDOF Collamer® Lens is Designed to Improve Near, Intermediate and Distance Vision

LAKE FOREST, Calif. --(BUSINESS WIRE)--Jul. 31, 2019-- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced the submission of its multi-site European pivotal clinical trial data for

STAAR Surgical Reports Record Second Quarter Results for Total Revenue, ICL Sales and ICL Units

LAKE FOREST, Calif. --(BUSINESS WIRE)--Jul. 31, 2019-- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today reported financial results for the second quarter ended June 28, 2019 .

STAAR Surgical to Report Second Quarter Results on July 31, 2019

LAKE FOREST, Calif. --(BUSINESS WIRE)--Jul. 10, 2019-- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that it will release financial results for the second quarter ended June 28,

STAAR Surgical Frequently Asked Questions

  • When was STAAR Surgical founded?

    STAAR Surgical was founded in 1982.

  • Who are STAAR Surgical key executives?

    STAAR Surgical's key executives are Caren Mason, Deborah Andrews and Scott Barnes.

  • How many employees does STAAR Surgical have?

    STAAR Surgical has 475 employees.

  • What is STAAR Surgical revenue?

    Latest STAAR Surgical annual revenue is $124 m.

  • What is STAAR Surgical revenue per employee?

    Latest STAAR Surgical revenue per employee is $261 k.

  • Who are STAAR Surgical competitors?

    Competitors of STAAR Surgical include Carl Zeiss Meditec, Bausch Health Companies and Johnson & Johnson.

  • Where is STAAR Surgical headquarters?

    STAAR Surgical headquarters is located at 1911 Walker Ave, Monrovia.

  • Where are STAAR Surgical offices?

    STAAR Surgical has offices in Monrovia, Shanghai, Hamburg, Urayasu and in 3 other locations.

  • How many offices does STAAR Surgical have?

    STAAR Surgical has 7 offices.